Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- Leaps by Bayer leads $80M Series A financing for Cellino Biotech to autonomize stem cell therapy manufacturing
- Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant
- Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
- Pfizer shares in vitro efficacy of novel COVID-19 oral treatment against omicron variant
- GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
Research & Development
- New study suggests two paths toward ‘super immunity’ to COVID-19
- The cellular response that protects pigs from COVID-19
- An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections
- Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events
- WHO recommends two new drugs to treat patients with COVID-19
- Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19
- COVID-19 - Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose
Conferences & Events
- SMi Group's 13th Annual Conference: RNA Therapeutics 2022
- SMi's 5th Annual 3D Cell Culture Conference
- New vaccine ingredient shows promise
- Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai, ASC Therapeutics and Within3
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
Regulatory Affairs
- FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults
- FDA authorizes first oral antiviral for treatment of COVID-19
- FDA expands eligibility for Pfizer-BioNTech COVID-19 booster dose to 16- and 17-year-olds
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
- FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases